Autologous Stem Cell Transplant (ASCT)

Introduction

An autologous stem cell transplant is a treatment that uses your own blood-forming stem cells to rebuild your bone marrow after very high doses of chemotherapy. The word “autologous” simply means “from yourself.” Your stem cells are collected, stored safely, and then returned to you after the chemotherapy has done its work against the underlying disease.

If you or a family member has been told that autologous stem cell transplant is the next step in care, you are probably already living with a diagnosis such as multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, or another condition that responds to this approach. You may be feeling a mix of hope and worry. The transplant journey is demanding, but it is also a well-established part of modern blood cancer treatment, and most patients move through it with the support of a specialised team.

This article walks through what autologous stem cell transplant is, why it is used, how the process unfolds from collection to recovery, and what life looks like afterwards. It is written for patients and families who want to understand the road ahead in plain language.

What Is an Autologous Stem Cell Transplant?

An autologous stem cell transplant — often shortened to ASCT — is a procedure in which a patient’s own haematopoietic (blood-forming) stem cells are removed, stored, and later returned to the body after intensive chemotherapy. The aim of the chemotherapy is to destroy as much of the underlying disease as possible. Because such high doses also wipe out healthy bone marrow, the stored stem cells are needed to rebuild the blood system.

Stem cells in this setting are not embryonic stem cells. They are blood-forming cells that live mainly in the bone marrow and can develop into red blood cells (which carry oxygen), white blood cells (which fight infection), and platelets (which help blood to clot). When infused back into the bloodstream, these cells find their way to the bone marrow and begin producing new blood cells within a few weeks — a process called engraftment.

It is important to understand how an autologous transplant differs from an allogeneic transplant. In an allogeneic transplant, stem cells come from a donor — a sibling, family member, or unrelated matched donor. In an autologous transplant, the cells come from the patient. Because the cells are the patient’s own, there is no risk of graft-versus-host disease and no need for long-term immune-suppressing medication. The trade-off is that the transplanted cells cannot fight the disease themselves, which is why the high-dose chemotherapy carries the main treatment effect.

Autologous transplant is sometimes called “high-dose chemotherapy with autologous stem cell rescue,” which describes the logic of the treatment well: the stem cells “rescue” the bone marrow from the high-dose chemotherapy that targets the disease.

Why Is Autologous Stem Cell Transplant Performed?

Doctors consider autologous stem cell transplant for a number of blood cancers and certain other conditions, mainly where high-dose chemotherapy is expected to deepen and prolong remission.

Multiple Myeloma

Multiple myeloma is the single most common reason for autologous transplant worldwide. Major guidelines, including those from the National Comprehensive Cancer Network (NCCN), describe autologous transplant as a standard part of treatment for eligible patients with newly diagnosed multiple myeloma after initial drug therapy (called induction). It is also sometimes used at the time of relapse.

Hodgkin and Non-Hodgkin Lymphoma

For Hodgkin lymphoma and several types of non-Hodgkin lymphoma (such as diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma), autologous transplant is most often used when the disease has come back after first-line treatment or has not responded fully to it. The approach involves giving salvage chemotherapy first, confirming a good response, and then proceeding to transplant.

Other Conditions

Less commonly, autologous transplant is used in:

• Certain germ cell tumours that have relapsed
• Some autoimmune conditions such as multiple sclerosis or systemic sclerosis, in selected patients within specialist programmes
• Selected paediatric cancers, including some neuroblastomas and brain tumours
• Light chain (AL) amyloidosis

Whether autologous transplant is appropriate for a specific person depends on the disease, how it has responded to earlier treatment, the patient’s overall health, and the judgment of the treating team.

Who Is a Candidate?

Eligibility for autologous stem cell transplant is decided through a careful assessment. Transplant teams look at several factors together rather than any single test.

Common factors considered include:

• The underlying disease and its response to earlier treatment. Patients whose disease has responded well to induction or salvage chemotherapy generally have better transplant outcomes.
• Age and general fitness. Biological fitness matters more than chronological age. Many patients in their 60s and selected patients in their 70s undergo autologous transplant successfully if their organ function and performance status are good.
• Heart, lung, kidney, and liver function. These organs must be able to handle the stress of high-dose chemotherapy. Specific tests assess each.
• Active infections. Significant active infection usually needs to be treated first.
• Psychosocial support. Having a caregiver available during recovery is important because the post-transplant period is demanding.

The pre-transplant work-up typically includes blood tests, heart tests (such as an echocardiogram or MUGA scan), lung function tests, kidney function tests, dental review, and updated imaging or bone marrow studies to confirm the disease status. The transplant team uses this information to decide whether autologous transplant is the right next step and to plan the safest possible approach.

Alternatives to Consider

Autologous stem cell transplant is one option in a wider landscape of treatments for blood cancers. Whether it is the right path depends on the disease, prior treatment, and personal factors. Alternatives or complementary approaches that transplant teams may discuss include:

• Continued drug therapy without transplant. For some patients with multiple myeloma, ongoing combination therapy followed by maintenance treatment is being explored as an alternative to early transplant. For some lymphomas, modern chemotherapy regimens may produce durable remissions without transplant.
• CAR-T cell therapy. Chimeric antigen receptor T-cell therapy uses the patient’s own immune cells, re-engineered in a laboratory to attack cancer. CAR-T has become an important option for certain relapsed lymphomas and for some patients with relapsed myeloma. In some situations, it has changed when and whether autologous transplant is offered.
• Allogeneic stem cell transplant. Using donor stem cells is sometimes considered for diseases where the donor immune system can help fight the cancer. It carries different risks, including graft-versus-host disease.
• Bispecific antibodies and newer targeted drugs. Several new drug classes are now available for myeloma and lymphoma and are reshaping the treatment sequence.
• Clinical trials. Many transplant centres run clinical trials offering access to combinations or newer approaches that may suit specific patients.

Choosing among these options is a clinical decision made together with the haematology and transplant team, based on disease biology, prior response, and the patient’s overall situation.

The Stages of Autologous Stem Cell Transplant

An autologous stem cell transplant is not a single event but a series of carefully sequenced stages that unfold over several weeks. Understanding the stages can make the process feel less overwhelming.

Stage 1: Pre-Transplant Evaluation

Before anything begins, the transplant team confirms that the disease is in a suitable state and that the body can tolerate the planned treatment. Tests typically include:

• Detailed blood tests
• Bone marrow biopsy
• Imaging such as CT or PET-CT scans
• Heart and lung function tests
• Dental assessment (to treat any infection sources before transplant)
• Screening for viruses such as hepatitis B, hepatitis C, and HIV
• A central venous catheter is placed in a large vein, usually in the chest or neck, to allow blood draws, infusions, and stem cell collection

This is also when patients meet the transplant team in detail, discuss the plan, and arrange a caregiver and accommodation if needed.

Stage 2: Stem Cell Mobilisation

Stem cells normally live in the bone marrow, but for collection, they need to be coaxed out into the bloodstream. This is called mobilisation.

Mobilisation usually involves:

• Growth factor injections such as G-CSF (granulocyte colony-stimulating factor), given under the skin for several days. G-CSF tells the bone marrow to make many more stem cells and to release them into the blood.
• Chemotherapy mobilisation in some patients, where a dose of chemotherapy is given first and growth factor follows. This is called “chemo-mobilisation.”
• Plerixafor, a medication sometimes added when stem cell numbers are not high enough with G-CSF alone.

Mobilisation usually takes about a week to ten days. Side effects of G-CSF can include bone pain (often in the lower back, hips, and breastbone), headaches, and fatigue. These are temporary and usually manageable with simple pain relief.

Stage 3: Stem Cell Collection (Apheresis)

Once enough stem cells have moved into the bloodstream, they are collected through a procedure called apheresis. Blood is drawn from the central catheter and passed through a machine that separates out the stem cells, returning the rest of the blood to the patient. Each session takes about three to five hours, and one to several sessions may be needed depending on how many cells are collected each day.

The cells are counted in the laboratory. The team aims for a target number of CD34-positive cells (a marker for blood-forming stem cells) sufficient for one or sometimes two transplants. Once enough cells are collected, they are frozen in a special solution and stored at very low temperatures until they are needed.

The collection itself is usually comfortable. Some patients feel tingling around the mouth or in the fingers because of the anticoagulant used during apheresis; this is treated with calcium and is not dangerous.

Stage 4: Conditioning (High-Dose Chemotherapy)

After cells are safely stored, patients usually have a short break and then return for the next phase. This typically begins with hospital admission for a transplant centre stay.

Conditioning is the name given to the high-dose chemotherapy delivered just before the stem cells are reinfused. The specific regimen depends on the disease:

• For multiple myeloma, high-dose melphalan is the standard conditioning drug.
• For Hodgkin and non-Hodgkin lymphoma, a multi-drug regimen such as BEAM (carmustine, etoposide, cytarabine, melphalan) is commonly used. Other regimens exist and centres choose based on the disease and patient.

Conditioning is given over one to several days. Side effects begin shortly after and include nausea, vomiting, mouth sores (mucositis), diarrhoea, hair loss, and fatigue. Anti-nausea medications and supportive care are given throughout.

Stage 5: Stem Cell Infusion (Transplant Day)

The day the stem cells are returned is often called “Day 0.” The frozen stem cells are thawed at the bedside and infused into the bloodstream through the central catheter, much like a blood transfusion. The infusion itself takes anywhere from 30 minutes to a few hours.

The preservative used to freeze the cells (DMSO) has a distinctive smell that some patients notice as a taste in the mouth, sometimes described as garlic or sweetcorn. Mild side effects during the infusion can include flushing, nausea, a brief change in blood pressure, or a feeling of warmth. The nursing team monitors closely throughout.

Once the cells are in the bloodstream, they find their way back to the bone marrow on their own — a process called homing.

Stage 6: Engraftment and the Early Recovery Period

The days following Day 0 are typically the hardest part of the transplant. Blood counts fall to very low levels because the conditioning chemotherapy has wiped out the bone marrow and the new stem cells have not yet started producing blood cells. During this period, patients are vulnerable to:

• Infections, because white blood cell counts are very low
• Bleeding, because platelet counts are very low
• Fatigue and breathlessness, because red blood cell counts are low
• Mouth sores, which can make eating and drinking painful
• Nausea, diarrhoea, and loss of appetite

Supportive care during this time may include antibiotics, antivirals, antifungals, red blood cell and platelet transfusions, intravenous fluids, nutrition support, and strong pain relief for mucositis.

Engraftment — the point at which the new stem cells start producing measurable numbers of healthy blood cells — usually happens between day 10 and day 14 after the infusion for autologous transplants. The first sign is a rise in the neutrophil count, a type of white blood cell. Platelets and red cells generally recover a little later.

Most patients are discharged from hospital between two and four weeks after the transplant, depending on how engraftment progresses and how they have tolerated the high-dose chemotherapy.

Recovery After Discharge

The first three months after transplant are sometimes called the “Day 100” period because this is a standard milestone at which transplant teams formally reassess progress. During this time:

• Fatigue is the most common symptom and can last for many months.
• The immune system is still rebuilding. Patients are advised to avoid crowds, sick contacts, and foods that carry a higher infection risk (raw or undercooked meats, unpasteurised dairy, and similar).
• Frequent clinic visits and blood tests track recovery.
• Preventive medications continue, including antivirals, antifungals, and sometimes antibiotics.
• Taste changes, appetite changes, and digestive symptoms gradually improve.

Three to Twelve Months

Energy levels usually improve steadily, although many patients describe a stepwise recovery with good days and harder days. Hair regrows. Most people return to gradually increasing activity and many return to work in some form by six to twelve months, depending on the demands of their job and how their recovery has progressed.

The transplant team will plan vaccinations during this period. Childhood vaccines often need to be repeated because the immune system has effectively been “reset.” A vaccination schedule typically starts around six months and continues over the following one to two years.

Beyond One Year

Most physical recovery is complete by one to two years after transplant, although fatigue can linger longer. Long-term follow-up continues for years, with regular checks for disease response and for late effects of treatment.

Risks and Complications

Autologous stem cell transplant is generally safer than allogeneic transplant because the patient’s own cells are used, but it is still a major treatment with real risks. Transplant teams discuss these in detail before the procedure.

Early Risks

• Infection. The greatest risk in the early weeks. Even minor infections can become serious when blood counts are low. Fever during this period is treated urgently with broad-spectrum antibiotics.
• Mucositis. Painful inflammation of the lining of the mouth and digestive tract from high-dose chemotherapy. Can require strong pain relief and sometimes a temporary feeding tube or intravenous nutrition.
• Bleeding. Low platelets can lead to easy bruising, nosebleeds, or more serious bleeding. Platelet transfusions are given as needed.
• Nausea, vomiting, and diarrhoea. Common from conditioning chemotherapy.
• Engraftment syndrome. Fever, rash, and fluid retention that can occur around the time of engraftment in a small number of patients. Usually treated with short-course steroids.
• Organ stress. Heart, lung, kidney, and liver function can be temporarily affected by the conditioning regimen.

Late Risks

• Persistent fatigue. Can last many months and occasionally longer.
• Infertility. High-dose chemotherapy can affect fertility in both men and women. Fertility preservation options should be discussed before transplant for patients who may want children in the future.
• Early menopause in women of reproductive age.
• Cataracts, especially after certain conditioning regimens.
• Reduced bone density.
• Second cancers. A small long-term risk of treatment-related blood cancers (such as myelodysplastic syndrome or acute leukaemia) exists after high-dose chemotherapy. This is monitored through long-term follow-up.
• Cardiac and pulmonary late effects, depending on the conditioning drugs used.

Mortality

Treatment-related mortality with autologous transplant is low in experienced centres — significantly lower than with allogeneic transplant. The exact figure depends on the disease, patient age, fitness, and other factors, and is best discussed with the transplant team for an individual estimate.

Life After Autologous Stem Cell Transplant

Coming through a stem cell transplant is a significant achievement. Most patients describe the experience as life-changing, both physically and emotionally.

Disease Monitoring

Follow-up depends on the underlying disease. For multiple myeloma, regular blood tests track markers such as serum free light chains, M-protein, and immunoglobulin levels. For lymphoma, follow-up includes physical examination and imaging at intervals decided by the team. Maintenance treatment is often given after transplant, particularly for myeloma, where ongoing low-dose therapy has been shown in clinical studies to prolong remission.

Lifestyle and General Health

After transplant, attention to general health becomes especially important. This typically includes:

• Healthy eating with attention to food safety in the early months
• Gradual return to physical activity, building strength and stamina over many months
• Avoiding tobacco and limiting alcohol
• Sun protection, because skin sensitivity may increase
• Mental health support, which is widely encouraged because the emotional impact of transplant is often felt more strongly once the immediate medical demands ease
• Dental care, vision checks, bone density monitoring, and other general health screening as advised

Emotional Recovery

The emotional adjustment after transplant is often as significant as the physical one. Many patients describe the first months at home as a time of mixed feelings: relief at having come through, gratitude, but also anxiety about recurrence, fatigue that is hard to explain to others, and a sense of being changed by the experience. These feelings are common. Counselling, peer support groups, and the transplant team’s psychosocial services can all help.

Returning to Work and Daily Life

The timeline for returning to work varies widely. Some people return part-time within a few months; others need a longer break. Pacing, communicating with employers, and protecting energy are practical priorities.

Autologous Stem Cell Transplant in Children

Children may undergo autologous stem cell transplant for certain solid tumours and lymphomas. The most common paediatric indications include:

• High-risk neuroblastoma, often with tandem (two) autologous transplants as part of a longer treatment plan
• Some relapsed Hodgkin and non-Hodgkin lymphomas
• Selected brain tumours such as medulloblastoma in young children, where transplant may be used to avoid or reduce radiation
• Selected germ cell tumours that have relapsed

The overall process is similar to adults, but with important paediatric considerations:

• Doses of chemotherapy are calculated by weight or body surface area.
• Mobilisation and apheresis are adapted for smaller body size.
• Play specialists, child psychologists, and paediatric-trained nursing teams are core members of the care team.
• Schooling support during isolation periods is built into many paediatric transplant programmes.
• Long-term follow-up is especially important because children have many years ahead in which late effects on growth, fertility, hormones, learning, and second cancers must be monitored.

Parents are heavily involved at every stage. Paediatric transplant centres typically have dedicated family accommodation and support services to help families through what is often a months-long process.

Frequently Asked Questions

How long will I be in hospital for an autologous transplant?

Most adults stay in hospital for about two to four weeks, from the start of conditioning chemotherapy through engraftment and early recovery. Some centres run outpatient or partial-outpatient transplant programmes for selected patients. Children typically stay longer.

Will my hair fall out?

Yes, the high-dose conditioning chemotherapy almost always causes hair loss. Hair usually starts to regrow within a few months after transplant. The new hair may initially have a different texture or colour before returning to normal over time.

Will I need someone with me during recovery?

Yes. A dedicated caregiver is one of the requirements most transplant centres set before proceeding. The caregiver helps with daily activities, watches for signs of infection, supports medication routines, and provides emotional presence during a demanding time, particularly in the first weeks after discharge.

Can the cancer come back after autologous transplant?

Yes, relapse is possible and the risk depends on the disease, how well it responded before transplant, and other factors. Autologous transplant aims to deepen and prolong remission rather than guarantee cure for most indications. Maintenance therapy after transplant is increasingly used to lower the risk of relapse in diseases such as multiple myeloma.

Can I have a second autologous transplant later?

In some situations, yes. Tandem transplants (two transplants planned in sequence, weeks to months apart) are part of standard treatment for some patients with multiple myeloma. A second transplant at the time of relapse is also possible for selected patients. This is why many centres collect enough stem cells at the first mobilisation to allow for a future transplant if needed.

What is the difference between bone marrow transplant and stem cell transplant?

The terms are often used interchangeably. Historically, stem cells were collected directly from the bone marrow under anaesthesia. Today, stem cells are almost always collected from the bloodstream after mobilisation, which is easier and more efficient. The end result — reinfusion of blood-forming stem cells — is the same.

Will my immunity ever fully recover?

For most patients, yes. The immune system rebuilds over many months. Vaccinations are repeated to restore protection. By one to two years after transplant, most patients have a functional immune system again, although some types of immunity recover more slowly than others.

Will my fertility be affected?

High-dose chemotherapy can affect fertility, sometimes permanently. For patients who may want children in the future, fertility preservation options (such as sperm banking, egg freezing, or embryo freezing) should be discussed before transplant. Transplant teams generally bring this up routinely with patients of reproductive age, but it is reasonable for patients to raise it as well.

How do I know if the transplant has worked?

Success is measured in two ways: short-term success means safe recovery of blood counts and a return to good general health; longer-term success means deep and lasting response of the underlying disease. Disease response is tracked through blood tests, bone marrow studies, and imaging, depending on the condition. Your transplant team will explain the markers that apply to you.

What does “Day 100” mean?

Day 100 is the standard point at which transplant teams review progress after autologous transplant. By this time, blood counts have usually recovered, the immune system has begun to rebuild, and the first assessment of disease response can typically be done. It is a milestone, not a finish line.

Conclusion

Autologous stem cell transplant is a demanding but well-established treatment that has changed outcomes for many patients with multiple myeloma, lymphoma, and selected other conditions. It uses your own stem cells to rebuild the bone marrow after high-dose chemotherapy designed to push the disease into deeper remission.

The process unfolds in stages over several weeks: evaluation, mobilisation, collection, conditioning, infusion, engraftment, and a longer recovery that continues for many months. Each stage has its own challenges and its own supports. The first few weeks are the hardest physically; the months that follow ask for patience as energy, immunity, and confidence return.

Understanding what to expect can make a difficult treatment feel more manageable. Every transplant journey is individual, and the details of the plan — including the conditioning regimen, the timing, the role of maintenance therapy, and the long-term follow-up — are shaped by the underlying disease, prior treatment, and personal factors. The transplant team is the right partner for these decisions, and the conversations along the way are an important part of care.